Newly arrived on Nasdaq, Poseida quietly signals a clinical hold triggered by a patient death in PhI — shares crater
Sometime earlier today the FDA slapped a full clinical hold on their Phase I study of their second autologous program for P-PSMA-101 in metastatic castrate resistant prostate cancer.
According to an SEC filing, which hasn’t triggered a release from the company, a patient in the early study was hospitalized and then died of hepatic failure 17 days after receiving their BCMA CAR-T.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.